Affimed NV (AFMD)
4.30
+0.24
(+5.91%)
USD |
NASDAQ |
May 31, 16:00
4.32
+0.02
(+0.47%)
After-Hours: 20:00
Affimed Cash from Financing (Quarterly): -1.482M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.482M |
| September 30, 2023 | -1.748M |
| June 30, 2023 | -2.824M |
| March 31, 2023 | -0.6809M |
| December 31, 2022 | 3.594M |
| September 30, 2022 | -5.657M |
| June 30, 2022 | 95.64M |
| March 31, 2022 | -0.1896M |
| December 31, 2021 | 32.89M |
| September 30, 2021 | -2.931M |
| June 30, 2021 | 1.332M |
| March 31, 2021 | 126.76M |
| December 31, 2020 | 42.63M |
| September 30, 2020 | 14.82M |
| June 30, 2020 | 22.63M |
| March 31, 2020 | -0.9943M |
| December 31, 2019 | 31.43M |
| September 30, 2019 | -0.8415M |
| June 30, 2019 | -0.3986M |
| March 31, 2019 | -1.039M |
| December 31, 2018 | -0.4011M |
| September 30, 2018 | -1.495M |
| Date | Value |
|---|---|
| June 30, 2018 | -1.724M |
| March 31, 2018 | 27.82M |
| December 31, 2017 | 3.196M |
| September 30, 2017 | 2.950M |
| June 30, 2017 | 3.294M |
| March 31, 2017 | 17.51M |
| December 31, 2016 | 0.9431M |
| September 30, 2016 | -0.801M |
| June 30, 2016 | -0.4033M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 21.10M |
| September 30, 2015 | 1.246M |
| June 30, 2015 | 37.02M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -0.9798M |
| September 30, 2014 | 59.05M |
| June 30, 2014 | 1.629M |
| March 31, 2014 | 0.00 |
| December 31, 2013 | -0.0015M |
| September 30, 2013 | 3.873M |
| June 30, 2013 | 2.88M |
| March 31, 2013 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.657M
Minimum
Sep 2022
126.76M
Maximum
Mar 2021
18.63M
Average
-0.1896M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| CureVac NV | -1.221M |
| InflaRx NV | -0.0931M |
| MorphoSys AG | -- |
| BioNTech SE | -8.472M |
| Immatics NV | 189.70M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.02M |
| Cash from Investing (Quarterly) | 1.755M |
| Free Cash Flow | -123.42M |
| Free Cash Flow Per Share (Quarterly) | -1.842 |
| Free Cash Flow to Equity (Quarterly) | -26.63M |
| Free Cash Flow to Firm (Quarterly) | -27.55M |
| Free Cash Flow Yield | -192.1% |